Bio-Techne Reports Strong Q3 2025 Revenue Growth

Bio-Techne ( (TECH) ) has released its Q3 earnings. Here is a breakdown of the information Bio-Techne presented to its investors.

Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, aiding in drug discovery and clinical testing. In its third-quarter fiscal 2025 earnings report, Bio-Techne announced a 6% increase in organic revenue, reaching $316.2 million, with adjusted earnings per share rising to $0.56 from $0.48 in the previous year. The company experienced strong growth in its Protein Sciences segment, which saw a 7% organic revenue increase, driven by improved pharma market conditions and effective commercial execution. Despite a decrease in GAAP earnings per share to $0.14 from $0.31, the adjusted operating margin improved to 34.9%, reflecting successful profitability initiatives. Looking ahead, Bio-Techne’s management remains optimistic about navigating the current market environment, supported by its robust portfolio and experienced leadership team.